Effective management of hypotension refractory to vasoconstrictors in severe sepsis is limited. A new strategy to ameliorate endotoxemic hypotension by inducing endothelium-dependent constriction of large arteries was assessed.
Introduction
The incidence and mortality of sepsis syndrome remain serious clinical problems (Azevedo et al., 2008; Fink et al., 2013; Investigators et al., 2014) , and the effective clinical management of acute severe sepsis remains limited (Muller, 1991; Van Dien et al., 2001; Cheng et al., 2007; Azevedo et al., 2008) . The pathogenesis of sepsis is highly complex and is not fully understood. Most proposed therapeutic strategies including inhibitors of the synthesis of cytokines, eicosanoids, or NO, and antagonistic agents targeting the toll-like receptors (Fink et al., 2013) for severe sepsis have failed or produced inconsistent clinical trials (Muller, 1991; Vincent et al., 2000; Van Dien et al., 2001; Lopez et al., 2004; Cheng et al., 2007; Azevedo et al., 2008; Fink et al., 2013) . In severe sepsis, for example, there is an excessive and generalized activation of the endothelium, which is differentially regulated in space and time, revealing endothelial cell (EC) heterogeneity and vascular diversity (McCuskey et al., 1996; Aird, 2003) . The activated endothelium undergoes site-specific changes, leading to increased leukocyte adhesion, a shift in the haemostatic balance towards a procoagulant phenotype and generation of reactive oxygen species, causing altered regulation of vasomotor tone and organ failure (Aird, 2003; Shapiro et al., 2010; Kimmoun et al., 2013) . Because of these complicated immunological, biochemical and pathophysiological changes in severe sepsis, attempt to target one specific pathway, component, or cytokine involved in the host response, therefore, is one major potential shortcoming of therapeutic approaches in this problem (Fink et al., 2013) .Mortality in sepsis is not caused by the syndrome per se, but rather the problems associated with it, including acute respiratory disease syndrome, systemic arterial hypotension and vasoplegia and encephalopathy (Fink et al., 2013) . Thus, in severe sepsis with hypotensive shock, the problem of sepsis pharmacotherapy might be better controlled by including vasoconstrictor drugs. For example, the vasopressin V 1 receptor agonist FE 202158 (selepressin), was shown to ameliorate hypotension and increase survival rate in experimental animals (Laporte et al., 2011) . FE 202158 (Laporte et al., 2011) and arginine vasopressin (AVP) raise systemic BP in hypotensive shock subjects by directly constricting the vascular smooth muscle (Kimmoun et al., 2013) . One possible concern for these direct smooth muscle constrictors, however, is their coronary vasoconstricting effect, which may decrease coronary blood flow and potentially worsen the already weakened hearts in both experimental and clinical settings (Russell, 2007; Kimmoun et al., 2013) .
In the present study, we examined an alternative approach to treat endotoxemic hypotension by inducing endothelium-dependent vasoconstriction of endotoxemic large arteries. This is based on our preliminary results showing that intravascular oroxylin-A (OroA, a flavonoid from Scutellaria radix or Huang Qin, see Supporting Information Figure S1 ) , immediately reversed the decreased mean arterial pressure (MAP) in rats with LPS-induced endotoxemia, and that OroA constricted the endotoxemic isolated arteries. In addition, OroA, via its anti-inflammatory activities, attenuated LPS-induced lung inflammation and injury and the expression of proinflammatory genes in BV-2 microglial cells (Liu et al., 2012b) along with an improved survival rate in endotoxemic hypotensive animals . Reports by others also have indicated that post-treatment with OroA inhibited cecal ligation and puncture (CLP)-induced sepsis-related systemic inflammation and abnormal coagulation via inhibiting endothelial protein C receptor (EPCR) shedding (Ku et al., 2013) . Because EPCR shedding is involved in the pathogenesis of sepsis (Kurosawa et al., 1998; Borgel et al., 2007) , OroA may be used to manage sepsis via amelioration of the EC function. Also, OroA ameliorates LPS-depressed cardiac functions by increasing coronary flow, indicative of coronary vasodilation, leading to positive inotropy (Liu et al., 2012a) . These anti-inflammatory and beneficial cardio-pulmonary effects of OroA with increased survival rate in LPS-induced endotoxemia suggest that OroA is most likely to ameliorate the functions of the microvasculature. The increase in MAP induced by OroA post-treatment in endotoxemic rats, therefore, is likely to be due to its constriction of large resistance arteries in different vascular beds.
It is, therefore, reasonable to propose that a rational acute management of endotoxemic hypotensive shock requires immediate increase of the systemic BP via constriction of large arteries, together with amelioration of the microcirculation to avoid organ damage. This is supported by the reported findings that infusion of nitroglycerin, a NO donor, in septic shock patients under vasopressor treatment, allows the enrollment of capillary arteries and improves microcirculation These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 ( a,b Alexander et al., 2015a,b) . (Spronk et al., 2002) . Numerous flavonoids including OroA, because of their general anti-inflammatory activities Garcia-Lafuente et al., 2009; Li et al., 2012; Liu et al., 2012b; Tseng et al., 2012) , suppress endotoxin-mediated endothelial inflammation and ameliorate EC functions of large arteries and microvessels. Accordingly, we have examined the antihypotensive effects of OroA and its possible mechanism of action of vasoconstriction in large resistance arteries of endotoxemic rats. Our findings indicated that OroA post-treatment (i.v. or i.p.) promptly reversed systemic hypotension in endotoxemic rats in vivo and induced endothelium-dependent constriction of isolated endotoxemic mesenteric arteries. The vasoconstriction was mediated predominantly by endothelium-derived ET-1 via activation of the Rho A/Rho-associated protein kinase (ROCK) pathway in the vascular smooth muscle cells (SMCs). In addition, OroA inhibited iNOS-catalysed systemic NO synthesis, providing additional means to decrease vasodilation mediated by NO and NO suppression of RhoA/ROCK-activities (Liao et al., 2013) .
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Methods
General procedures
All animal care and experimental procedures complied with the NIH guidelines for the care and use of laboratory animals and were approved by the Animal Care and Use Committee of Tzu Chi University. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Eight-week-old male Sprague-Dawley rats weighing 300-350 g were housed under standard conditions at the Animal Center of Tzu Chi University. All animals had ad libitum access to standard chow and water. Rats were kept under pathogen-free conditions and under a 12 h day/night cycle.
Endotoxemia was induced by injection of LPS (10 mg·kg
À1
, i. v.), based on our previous reports (Liu et al., 2012a; Tseng et al., 2012) . Rats were anaesthetized with urethane (0.5 g·kg
; i.p.) and a PE-50 catheter was inserted into the left femoral artery for recording MAP and heart rate (HR) through a polygraph recorder (MP 30; BIOPAC Instrument, Goleta, CA, USA). The right femoral vein was cannulated for administering experimental drugs and collecting blood samples. Animals were allowed to stabilize for 1 h before the scheduled experiments. LPS serotype 0127:B8 [Escherichia coli (E. coli) LPS] was dissolved in sterile physiological saline immediately before use. All invasive procedures were carried out under aseptic conditions. After LPS administration, animals were monitored for changes in MAP and HR for 24 h.
In order to investigate therapeutic effects of OroA posttreatment on LPS-induced sepsis, animals were divided randomly (Curtis et al., 2015) into six groups: (1) iv Sal(1 h)/ ivSolv1 or ivSal(6 h)/ivSolv1 (Control) group: 1 or 6 h after i.v. injection of normal saline, animals were injected with solvent1 (Solv1: saline plus Tween 80 in a 9:1 ratio, i.v., n = 7); (2) ivLPS(1 h)/ivSolv group: 1 h after receiving LPS (10 mg·kg À1 , i.v.), animals were injected with Solv1 (i.v., n = 13); (3) ivLPS (1 h)/ivOroA group: 1 h after LPS (i.v.) challenge, animals were injected with OroA (15 mg·kg À1 , i.v., n = 8); (4) ivLPS (6 h)/i.v. Solv group: 6 h after LPS (i.v.) challenge, animals were injected with Solv1 (i.v., n = 6); (5) ivLPS(6 h)/ivOroA group: 6 h after LPS (i.v.) challenge, animals were injected with OroA (15 mg·kg À1 , i.v., n = 9); and (6) ivLPS(6 h)/ivWogo or Bai group: 6 h after LPS (i.v.) challenge, animals were injected with wogonin (Wogo) or baicalein (Bai) (15 mg·kg À1 , i.v., n = 6). OroA, wogonin and baicalein were dissolved in Solv1 and mixed by ultrasonication. Changes of haemodynamics were measured in vivo and the reactivity of isolated mesenteric arteries by blood vessel myography. Twenty-four hours after LPS challenge, animals were killed, mesenteric arteries and blood samples were removed and examined for reactivity and NO concentrations respectively, as detailed below.
Preparation of OroA-containing solutions (Solv1 and Solv2)
OroA was dissolved in two different solvent solutions. Solv1 contained normal saline plus Tween 80 at 9:1 ratio. This solution containing OroA was ultrasonicated and was used for i. v. or i.p. injection in whole animal studies. OroA dissolved in solvent 2 (Solv2), which consisted of rat serum and DMSO (0.1%) was used to examine its effects on isolated arteries in blood vessel myography. The rat serum was prepared as follows: blood samples (1ml) were collected via the right femoral artery and without anticoagulant. Samples were centrifuged at 1,721 x g for 10 min to separate the serum from the cells. The serum samples were stored at 4°C until used for making Solv2. For each experiment, 100 mM stock OroAwas diluted to 1 mM with rat serum.
Blood vessel myography
Rats were anesthetized by intraperitoneal injection of urethane (0.5 g/kg), mesenteric arteries were isolated and placed in prewarmed Krebs bicarbonate solution equilibrated with 95% O2 and 5% CO2 at room temperature. The composition of Krebs solution is (mM): NaCl 120, KCl 5.4, CaCl2 1.25, MgSO4 1.2, NaHCO3 25.6, ethylenediamine-tetraacetic acid (EDTA) 0.03, L-ascorbic acid 0.1, glucose 11, pH 7.4. Connective tissue and fat surrounding the arteries were removed, under a dissecting microscope, and processed for studying vessel reactivity using myography, as described by Lee et al. (1976. For control experiments, the arterial segments with or without endothelium (by mechanical denundation, as described below) were preincubated with normal saline or Solv2, for 3 hours. In the presence of the active muscle tone, OroA, wogonin, or baicalein (1-10 μM), dissolved in Solv2, was applied to the bath to induce a response. The arteries were washed with pre-warmed Krebs solution for 15 min between applications of OroA. The endothelial cells of arterial ring segments were mechanically removed by a standard brief gentle rubbing of the intimal surface with a stainless steel rod with a diameter (28-30 gauge) equivalent to the lumen of the arteries. A complete denudation of endothelial cells was ascertained by lack of ACh (0.1-1 M)-inducing relaxation. At the end of each experiment, maximal contraction was induced by 75 mM KCl. The magnitude of OroA-induced contraction was expressed as the percent of KCl-induced maximal contraction. To examine effects of experimental drugs on OroA-induced vasoconstriction, the experimental drugs were applied and incubated for 15 min before addition of OroA.
NO measurement
Plasma NO was measured by the Griess reaction, as described by Tseng et al. (2012. Briefly, frozen plasma samples were thawed and deproteinized by incubation with 95% ethanol at 4°C for 60 min, and centrifuged for 10 min at 12,235 x g. supernatant sample (0.1mL) was incubated for 5 min with 100 μl Griess reagent (containing 0.1% N-1-napthylethylenediamine dihydrochloride, 10% sulfanilamide in 5% phosphoric acid; Sigma Chemicals) in 96-well plates. Standard nitrite salt solutions (0-100 μM) were used. Absorbance of the reaction product was measured at 550 nm. Plasma nitrite concentrations (μM) were calculated from the standard curve.
Effects of OroA on endothelial ET-1 and ECE mRNA expression and ET-1 release
Continuing from blood vessel myography study and after verifying the presence of functional endothelium by the presence of ACh-induced relaxation of phenylephrine (3 μM)-contracted arteries, a wash with pre-warmed Krebs solution, and a similar magnitude of active muscle tone was induced by phenylephrine. LPS (200 ng mL -1 ) then was added and incubated for 3 hours, which caused decreased muscle tone (relaxation) by 30%~50%. In the presence of residual active muscle tone, OroA (3 μM) was applied to the bath to induce a contractile response lasting for 15 min. The artery then was washed with prewarmed fresh Krebs solution and incubated for 15 min before addition of OroA (3 μM) which induced a constriction lasting for 15 min before washing with fresh Krebs solution again. After incubation in the normal Krebs solution for 15 min, OroA (3 μM) was administered for the third time to induce vasoconstriction lasting for 15 min. Accordingly, each artery had a total of 45 min contact incubation with OroA, and was 75 min after the initial incubation with OroA. At the end of the third contraction by OroA, the arteries were washed with Krebs solution and processed for immunohistochemical studies. For measuring mRNA and proteins of ET-1 and ECE in the arteries, and the release of endothelial ET-1 into the medium, a larger mass of arteries were used in order to enhance the sensitivity. Pooled mesenteric arteries (0.05 g) were first incubated with LPS, and followed by applications of OroA (3 times) with 3 washes with fresh Krebs solution in between, using the protocol as described above except that these arteries were not subjected to contraction/relaxation studies. For measuring release of ET-1, conditioned medium, after incubating with OroA (3 μM) for 15 min in the 3 rounds were collected (1ml conditioned medium was collected in each round), and processed for ET-1 assay. ET-1 concentration was analyzed by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Enzo Life Sciences, Lausen, Switzerland) following the manufacturer's instructions.
ET-1 immunofluorescence
Standard immunofluorescence techniques were used, as described previously . Briefly, 2 μM paraffin-embedded tissue sections from the mesenteric arteries were processed through antigen retrieval buffer, permeabilised with Triton X-100 for 30 min, blocking of non-specific interaction with normal serum (BioGenex, San Ramon, CA) for 1 h, followed by washing and reaction with goat ET-1 polyclonal antibody (1:75, Santa Cruz Biotechnology, CA, USA), rabbit CD31 polyclonal antibody (1:100, Abcam, Cambridge, UK), anti-goat IgG Hilyte Fluor 555-labelled antibody (1:200, AnaSpec, Fremont, CA, USA) or anti-rabbit IgG Hilyte Fluor 488-labelled antibody (1:200, AnaSpec). Some sections were processed by incubation with secondary antibodies only serving as a negative control. Cell nuclei were counter-stained with DAPI (1:200, KPL, Washington D.C, USA) for 20 min. All sections were mounted with a water-soluble mounting media and examined under an Olympus BX43 fluorescent microscope with a microscope digital camera system DP-72 (Olympus, Tokyo, Japan). Six to nine sections were obtained from each tissue block per animal. Accordingly, at least 36 sections were obtained from six animals, and among them, 36 sections were randomly selected for statistical analysis. All sections were analysed and the intensity of red fluorescence was measured by IMAGE J software (National Institute of Mental Health).
Immunoassay
Protein concentrations were quantified with bicinchoninic acid protein assay reagent (Pierce Chemicals, Rockford, IL, USA) . Aliquots of the extracts were diluted in a 1:4 ratio with sample buffer [0.25 M Tris-Cl pH 6.8, 2% 2-mecaptoethanol, 8% SDS, 0.02% bromophenol blue and 40% glycerol] and boiled for 5 min at 100°C. All protein extracts were analysed simultaneously for protein concentration to ensure subsequent equal protein loading between samples. Protein extracts were separated on 10% SDS polyacrylamide gels (100 μg of protein per lane) and transferred onto a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA) by semidry electroblotting (Amersham Biosciences, Buckinghamshire, UK) for 45 min. Blots were blocked for 2 h at room temperature with 5% non-fat milk in Tri-buffered saline with 0.25% Tween 20 and then washed in TBS-T buffer solution. Antibodies used included anti-iNOS mouse antibody (1:500, BD Transduction, San Jose, CA, USA), antiendothelin-1 receptor mouse antibody (1:250, BD Transduction), anti-endothelin-converting enzyme (ECE) rabbit polyclonal antibody (1:1000, Abcam), anti-IκB rabbit polyclonal antibody (1:500, Santa Cruz Biotechnology), anti-ET-1 goat polyclonal antibody (1:1000, Santa Cruz Biotechnology), anti-ROCKII-phospho-Ser 1366 rabbit polyclonal antibody (1:500, GeneTex, Irvine, CA, USA) and anti-RhoA rabbit monoclonal antibody (1:2000, GeneTex, Irvine, CA, USA) in TBS-T buffer solution at 4°C for overnight. After wash, blots were exposed to horseradish peroxidaseconjugated anti-mouse IgG, anti-rabbit and anti-goat secondary antibodies (1:2000, KPL) for 1 h at room temperature, and immunoreactivities were visualized using an enhanced chemiluminescence detection system (PerkinElmer life science, Waltham, MA, USA). After stripping, blots were stained with a mouse anti-actin antibody (1:4000, Thermo Fisher Scientific, Rockford, IL, USA) for normalization to equal protein loading. After scanning blots into a computer, individual bands were analysed by IMAGE J software (National Institute of Mental Health).
Real-time RT-PCR for ET-1 and ECE gene expressions
Total RNA was extracted from the mesenteric arteries using TRIzol (Invitrogen, Carlsbad, CA, USA) according to our previous report (Liu et al., 2012b) . mRNA samples were quantified by spectrophotometer, and equal amounts of mRNA were reversely transcribed into first-strand cDNA by Super Script kit (Invitrogen). PCR amplifications were performed in triplicate using mixture of Master SYBR Green supermix (Roche, Mannheim, Germany), cDNA and specific primers ET-1, ECE and GADPH. The real-time PCR were performed for 45 cycles of 95°C for 15 s and 60°C for 1 min using an ABI Prism 7300. For detailed PCR-primers information, see Supporting Information methods.
Immunofluorescence assays for phosphorylated ROCK (p-ROCK)
Immunocytochemistry was used to assess the expression of p-ROCK in the mesenteric arteries . The arterial segments with endothelium and those without endothelium (denudation by mechanical rubbing of the intimal surface with a stainless steel rod) (Lee et al., 1976) were incubated in Krebs solution (37°C) containing LPS (200 ng·mL) for 3 h. After washing, OroA, wogonin or baicalein (3 μM), which was dissolved in Solv2, was added to the incubation bath in the presence or absence of receptor antagonists for ET A (BQ123, 10 μM) or ET B receptors (BQ788, 10 μM). To examine whether OroA-induced vasoconstriction was dependent on intact endothelium, adjacent segments of arteries, one with intact endothelium and the other without endothelium were examined for comparison. All arteries were fixed in 4% paraformaldehyde (pH 7.6, Sigma-Aldrich, St. Louis, MO, USA), dehydrated through a graded series of ethanol (75% for 30 min, 80% for 60 min, 95% for 3 h and 100% for 30 min), embedded in paraffin and processed for demonstrating p-ROCK immunoreactivities. Then, paraffinembedded cross sections (0.5 μm) of the mesenteric arteries were cut with a microtome (Leica; Leica Microsystems, Wetzlar, Germany) and processed through antigen retrieval protocol, permeabilized with Triton X-100 for 60 min, blocking non-specific interaction with normal serum (Biogenx) for 2 h, followed by washing and reaction with rabbit anti-ROCKII-phospho-Ser 1366 polyclonal antibody (1:150, GeneTex), mouse anti-beta actin monoclonal antibody (1:100, Thermo Fisher Scientific), anti-rabbit-IgG Hilyte Fluor 555-labelled antibody (1:200, AnaSpec) and anti-mouse-IgG Hilyte Fluor 488-labelled antibody (1:200, AnaSpec) according to our previous report . Some sections were processed by incubation with secondary antibodies only serving as a negative control. Cell nuclei were counter-stained with DAPI (1:200, KPL) for 20 min. All sections were mounted with a water-soluble mounting media and examined under an Olympus BX43 fluorescent microscope with a digital camera system DP-72 (Olympus). The intensity of red fluorescence in all sections were analysed and measured by using IMAGE J software (NIH).
Quantification of immunofluorescence assays for p-ROCK and ET-1
The standardized relative quantification of immunofluorescence in tissue sections was carried out according to Arqués et al. (2012. For details, see Supporting Information methods.
Measurement of RhoA activity
The GTP-linked immunosorbant assay (G-LISA, RhoA Activation Assays Biochem Kit, Cat.#BK124; Cytoskeleton, Inc., Denver, CO, USA) was used to measure the RhoA activity of the mesenteric arteries with or without endothelium according to the established protocol (Liao et al., 2013) .
Data analysis
The experimental data are presented as means ± SEM. All data were analysed by statistical software GRAPHPAD PRISM 5.0 (GraphPad Software Inc., San Diego, CA, USA). Statistical analysis was performed using one-way ANOVA. Post hoc comparisons between the groups were performed by Bonferroni multiple comparisons test. A P value less than 0.05 was considered statistically significant.
Materials
OroA and wogonin were isolated and purified according to our previous report . 
Results
OroA post-treatment promptly reversed diminished MAP and HR in LPS-induced endotoxemic rats
The MAP ( Figure 1A and C) and HR (Figure 1B and D) in the control and experimental groups were not different. Following LPS (10 mg·kg À1 , i.v.) treatment, MAP of the rats was markedly decreased in the first hour, followed by a slight recovery before continuous decline in the following 24 h ( Figure 1A ). In parallel, HR was increased substantially during the first 8 h followed by a significant decrease at 12h after LPS challenge ( Figure 1B ). Administration of OroA (15 mg·kg À1 , i.
v.) 1 h after LPS-challenge did not affect the initial decrease of MAP. It, however, facilitated the recovery to normal MAP and prevented further falls in subsequent hours ( Figure 1A ). This treatment of OroA did not significantly attenuate the tachycardia in the early phase (from the third to ninth hour), but reversed the decreased HR during the subsequent hours to nearly control values (12 h after LPS treatment) ( Figure 1B Figure S2A and B). The MAP and HR in control groups (i.v. Solv1 administered 1 h after saline challenge) remained normal in the course of entire experiments ( Figure 1A and B). Furthermore, OroA (15 mg·kg À1 , i.v.) administered 6 h after LPS challenge (10 mg·kg À1 , i.v.) immediately reversed the severe hypotension ( Figure 1C and Supporting Information Figure S2C ) and the severe bradycardia ( Figure 1D ) towards normal ranges within 10-20 min. The successful reversal rates, however, were variable in three different series of studies in three different time periods: 70% (21 of 30 rats, period 1), 40% (12 of 30 rats, period 2) and 50% (15 of 30 rats, period 3) in each series of study. Both reversed MAP and HR remained stable in normal ranges until the animals were killed 24 h after LPS challenge ( Figure 1C and D) . The MAP and HR in the control group (OroA administered 6 h after saline challenge) remained normal in the course of the experiments ( Figure 1C and D). Wogonin or baicalein (both flavonoids have close structural similarity to OroA, see Supporting Information Figure S1 ) in similar concentrations (15 mg·kg À1 , i.v.) did not affect the depressed MAP or HR (Supporting Information Figure S2D and E).
OroA induced endothelium-dependent, sustained contractions of mesenteric arteries, isolated from normal rats and incubated with LPS in vitro
In isolated mesenteric arteries with intact endothelium, verified by ACh-induced vasorelaxation in the presence of phenylephrine (3 μM)-induced active muscle tone ( Figure 2A , B and C), addition of LPS (200 ng·mL
À1
, in Figure 2A ), but not Solv2 ( Figure 2B ) or saline (0.9% normal saline, in Figure 2C ) into the bath for 3 h caused relaxation of the active muscle tone. At the end of 3 h incubation, the arteries constricted immediately upon application of OroA (1-10 μM, dissolved in Solv2) in a concentrationdependent manner (Figures 2A and E) . This OroA-induced vasoconstriction was not observed in LPS-incubated arterial rings Figure 2D and E). The successful rates of OroA in inducing immediate constrictions in the mesenteric arteries with intact endothelium (one strategically selected arterial sample per rat) were 75% (15 of 20 rats from period 1 in vivo studies) and 45% (9 of 20 rats from period 3 in vivo studies). Furthermore, phenylephrinecontracted arteries with intact endothelium incubated in the presence of Solv2 or normal saline alone for 3 h did not constrict upon application of OroA (1-10 μM) ( Figure 2C ).
ET-1 receptor antagonists block OroA-induced constriction of LPS-pretreated mesenteric arteries
The sustained vasoconstriction, induced by OroA (1-10 μM) in mesenteric arterial rings with intact endothelium, after exposure to LPS and phenylephrine, as described above, was reversed by BQ123 and/or BQ788 (1-10 μM, ET A and ET B receptor antagonists, respectively) in a concentrationdependent manner ( Figure 3A , B and C). Similarly, pre-
Figure 4
Oroxylin-A (OroA) enhancement of LPS-induced ET-1 and endothelin-converting enzyme (ECE) expression in isolated mesenteric arteries. ET-1 gene and receptor expression in the control, LPS-treated (200 ng·mL
À1
) and LPS plus OroA (3 μM)-treated isolated mesenteric arteries with or without endothelium (EC+ or ECÀ, respectively) were examined 3 h after LPS challenge (panels A, B and C). The expression of both ET-1 and ECE mRNA (panels A and B, respectively) and proteins for ET-1 (panel D), ECE (panel E) and ET-1 receptor (panel F) in arterial preparations (EC+) was increased 3 h after LPS-challenge and was further enhanced 45 min following addition of OroA (panels A, B and C). Endothelial ET-1-immunofluorescence intensity (arrows) also was increased in LPS-treated (200 ng·mL
) for 8 h (panel G) and was further increased by addition of OroA (3 μM) (horizontal line 3 figure in panel G) in isolated mesenteric arteries with endothelium (EC+). In endothelium-denuded arteries (ECÀ), no endothelial ET-1-immunofluorescence was detected after LPS and OroA treatments (panels G). Double staining with CD31 as a marker for endothelial cell (EC) were performed. These are summarized in panel H. Panel I indicates that ET-1 concentrations in the Krebs solution containing segments of mesenteric arteries with endothelium were increased following incubation with LPS and was further increased by addition of OroA for 45 min. The nucleus in blue colour was stained with DAPI. SMC: smooth muscle cell. Scale bars represent 20 μm in Figure  D . Data are means ± SEM. *P < 0.05, significantly different between the compared groups. Numbers in the columns represent number of experiments.
treatments with BQ788 (1-10 μM) ( Figure 3D and E) and BQ123 (1-10 μM, Figure 3F ) also blocked OroA-induced constriction of PE-contracted arteries ( Figure 3D , E and F).
OroA-enhanced LPS-induced ET-1 and ECE expression and ET-1 release in the mesenteric arteries Seventy-five minutes following 3 h LPS (200 ng·mL À1 ) incubation in vitro, expression of ET-1 and ECE mRNA ( Figure 4A and B) and proteins ( Figure 4C , D, E and F) in isolated mesenteric arteries with ECs was significantly elevated compared to the normal saline-treated or Solv2-treated control arteries with ECs. The increased expression of both ET-1 and ECE mRNA and proteins in mesenteric arteries was further enhanced by addition of OroA (3 μM, dissolved in Solv2) and incubated for a total of 45 min. No increase in expression of either ECE or ET-1 in mesenteric arteries without endothelium was observed following incubation with LPS and/or OroA ( Figure 4A , B, C, D and E). In parallel, the endothelial ET-1-immunofluorescence intensity was increased in LPS-treated (200 ng·mL À1 ) for 3 h ( Figure 4G ) and was further increased in LPS plus OroA-treated (3 μM) groups ( Figure 4G ) in isolated mesenteric arteries with endothelium, which was coincident with the immunoreactive CD31 (marker for the EC). In endothelium-denuded arteries, no ET-1-immunofluorescence was detected after LPS and OroA treatments ( Figure 4G ). These results are summarized in Figure 4H . The release of ET-1 into the Krebs solution containing isolated mesenteric arteries with endothelium were increased following incubation with LPS for 3 h and was further increased following incubation in the presence of OroA (3 μM) for a total incubation time of 45 min ( Figure 4I ). In mesenteric arteries without endothelium, no release of ET-1 into the solution was detected even in the presence of LPS (200 ng·mL À1 ) and OroA (3 μM) ( Figure 4I ).
Furthermore, LPS and OroA treatments did not affect expression of the ET-1 receptors in mesenteric arterial preparations with or without endothelium (n = 6, Figure 4F ).
Blockade by ROCK inhibitors of OroA-induced constriction of LPS-pretreated arteries with intact endothelium
Mesenteric arterial rings with intact endothelium from normal control rats were incubated with LPS (200 ng·mL À1 ) for 3 h as described in Figure 3 , were repeatedly constricted by applications of OroA (3 μM, dissolved in Solv2) ( Figure 5A and B). The sustained vasoconstriction was blocked by Y27632 (0.05-1 μM, n = 6, Figure 5A ) or fasudil (1-10 μM, n = 6, Figure 5B ) in a concentration-dependent manner, as summarized in Figure 5C . Furthermore, pre-treatment with the selective ROCK inhibitor fasudil (1-10 μM, n = 5, Figure 5D and E) blocked OroA-induced vasoconstriction of phenylephrinecontracted arteries ( Figure 5D and E).
OroA-activated endothelium-dependent RhoA-activity and expression in vascular smooth muscle cells Figure 5F and G). The decreased RhoA activities in arteries with endothelium were reversed by OroA (3 μM), but not by wogonin or baicalein (3 μM) after incubation with each compound for 45 min (n = 6, Figure 5F and G). In contrast, in all arteries denuded of endothelium, OroA in similar concentrations did not affect the decreased RhoA-activity induced by LPS ( Figure 5F and G).
OroA-activated endothelium-dependent ROCK activities in the smooth muscle cell
In order to further explore the mechanism of action of OroA involving the RhoA/ROCK pathway in inducing endotheliumdependent constriction of the SMCs of LPS-treated arteries, we examined and compared expression of ET-1 and p-ROCK in the arteries with or without endothelium after OroA (3 μM) application, using by immunohistochemical methods ( Figure 5H ) treatment. The fluorescence intensities, however, were drastically increased after addition of OroA (3 μM) in arteries with endothelium, but not in arteries without endothelium ( Figures 5H and I ). Additions of wogonin or baicalein, on the other hand, did not increase fluorescence intensity of p-ROCK-immunoreactive smooth muscles in LPS-treated arteries with endothelium ( Figure 5I ). In parallel, the ratio of contracted SMCs (indicated by oval shapes of SMC and nuclei, horizontal line 3 pictures in Figure 5H ) to the relaxed SMCs (indicated by elongated SMC and nuclei, horizontal line 2 pictures in Figure 5H ) was decreased (indicative of more relaxed SMC) by LPS treatment ( Figure 5J ). The ratio of contracted over relaxed SMCs was enhanced (indicative of more contracted SMC) after addition of OroA in LPS-treated arteries with endothelium only ( Figure 5J ). The ratio of contracted to relaxed SMCs in arteries with endothelium following LPS treatment, however, was not affected and remained low after wogonin or baicalein treatment, or in OroA-treated endothelium-denuded arteries ( Figure 5J ).
Suppression by ET-1 receptor antagonists of OroA-induced p-ROCK-immunoreactivities in isolated LPS-pretreated mesenteric arteries
The mesenteric arterial rings with endothelium following incubation in Solv2 for 3 h exhibited basal expression of endothelial ET-1 and smooth muscle p-ROCK (phosphorylated ROCKII-phospho-Ser 1366 )-immunofluorescence (I) ( Figure 6A ), p-ROCK-fluorescence intensity ( Figure 6B ) and p-ROCK-proteins ( Figure C) . At the end of the 3 h incubation in the presence of LPS (200 ng·mL À1 ), immunoreactivity to ET-1 increased while that to p-ROCK remained unchanged in both arteries (representative pictures in Figure 6A ). Addition of OroA (3 μM) to the incubation medium containing LPS (LPS + OroA group) further increased ET-1 expression as indicated by ET-1 immunoreactivity ( Figure 6A ), ET-1 proteins ( Figure 6C and D) and ET-1 release ( Figure 6G ) in the arteries with endothelium. In this LPS + OroA group, expression of both immunoreactivity to p-ROCK and p-ROCK-proteins in mesenteric arteries was significantly increased ( Figure 6A , B and C). The increase of ET-1-and p-ROCK immunoreactivity induced by OroA (3 μM) in mesenteric arteries was blocked by combination of BQ123 and BQ788 (10 μM, the respective ET A and ET B receptor antagonists) as shown in LPS + OroA + BQ123-+ BQ788 group ( Figure 6A , B and C). In parallel, RhoA proteins in the mesenteric arteries with endothelium decreased significantly following LPS treatment (200 ng·mL À1 ) comparing with the non-treated basal controls ( Figure 6E ). The diminished expression in both arteries was significantly reversed by OroA (3 μM, dissolved in Solv2) in the absence of ET A and ET B receptor antagonists ( Figures 6E and F) .
OroA inhibition of NF-κB signalling in LPS-induced endotoxemic mesenteric arteries
Consistent with our previous results in lung tissues , OroA inhibited iNOS and NO production in endotoxemic mesenteric arteries (for detail, see Supporting Information Results). Twenty-four hours after LPS challenge (10 mg·kg À1 , i.v.), phosphorylated IκB in mesenteric arteries increased significantly (Lanes 2 and 5 in Supporting Information Figure S4A ) compared with that in normal control group (Lane 1 in Supporting Information Figure S4A ). This increase Figure 4 , ET-1 immunoreactivity (panels A and B), ET-1-proteins (panels C and D) and ET-1 released in Krebs incubation medium (panel G) increased in the arteries (EC+) after LPS treatment, and the increase was further enhanced by addition of OroA (3 μM) in the LPS + OroA group. In arteries of this group (LPS + OroA), OroA also increased the immunoreactivity to p-ROCK (middle bottom figure in panel A and panel B) and p-ROCK-proteins (panels C and F). The increased immunoreactivity to p-ROCK and -proteins in these arteries were reversed to the basal levels (for fluorescence, see right bottom figure of panel A. and for proteins. see panels C and F) by combined treatment of BQ123 and BQ788 (10 μM) (the LPS + OroA + BQ123 + BQ788 group). The relative percent of ET-1, RhoA and p-ROCK proteins was normalized to actin, which served as an internal control and summarized as the relative density in percent (%) of ET-1, RhoA and p-ROCK expression. *P < 0.05, significantly different as indicated. Numbers in the columns represent number of experiments. L: lumen. Scale = 20 μm in ET-1/CD31/DAPI panels and p-ROCK/Actin/DAPI panels. The overall summary is depicted in panel H. Expression of ET-1 vasoactive substances, which are in very low concentrations or absent in the endothelial cell (EC) of mesenteric arteries in normal rats, is increased in LPS-treated, endotoxemic arteries. Upon application of OroA, ET-1 is released to induce constriction of the vascular smooth muscle (VSMC) by acting on the ET A and ET B receptors, and RhoA. ET-1 also activates the RhoA and ROCK pathway, leading to contraction of the VSMC. In addition, OroA inhibits expression of inducible NO synthase (iNOS) on the blood vessel wall with decreased NO synthesis from Arg (L-arginine), providing additional mechanisms in directly diminishing vasodilation, and indirectly enhancing vasoconstriction via lessening NO inhibition of RhoA and ROCK activities.
was significantly reversed by OroA (15 mg·kg À1 , i.v.) administered 1 h (Lane 3 in Supporting Information Figure S4A ) or 6 h (Lane 6 in Supporting Information Figure S4A ) or by OroA (30 mg·kg À1 , i.p.) administered 1 h (Lane 4 in Supporting Information Figure S4A ) after LPS challenge. LPS challenge also caused phosphorylation of NF-κBp65 (Lanes 2 and 4 in Supporting Information Figure S4B ). The phosphorylation of NF-κBp65 was inhibited by OroA (15 mg·kg À1 , i.v.) given 1 h [ivLPS(1 h)]/ivOroA group, Lane 3 in Supporting Information Figure S4B ] or 6 h [ivLPS(6 h)/ivOroA group, Lane 5 in Supporting Information Figure S4B ] after LPS challenge.
Discussion
The major findings of the present study were that OroA posttreatment (i.v. or i.p.) 6 h after LPS-challenge promptly reversed the decreased MAP and HR to within normal ranges in 20 min and that OroA induced endothelium-dependent constriction of endotoxemic mesenteric arteries. The decrease of more than 40 mmHg of MAP and of more than 30% of the vascular tone of isolated arteries after LPStreatment in the present study suggests that the LPS-induced endotoxemia mimicked a severe septic shock (King et al., 2013) . These results suggest that OroA post-treatment is potentially beneficial for an emergency and life-saving purpose in established endotoxemic hypotensive shock. The anti-hypotensive effect of OroA is likely to be due to its induction of endothelium-dependent, RhoA/ROCK pathwaymediated, constriction of arteries in endotoxemic rats. OroA post-treatment also suppressed LPS-induced expression of systemic iNOS and NO synthesis. The decreased circulating NO concentration further facilitated OroA-induced endotheliumdependent vasoconstriction by decreasing vasodilation resulted from the diminished NO-cGMP coupling and from NO suppression of RhoA/ROCK-activities. It should be noted from the present findings and those by others that OroA per se does not cause any constriction of isolated arteries, with or without ECs obtained from LPS-untreated, normal, animals. In addition, baicalein and wogonin (which share similar basic chemical structures of OroA) did not reverse the hypotension or the bradycardia in endotoxemic rats, or induce constriction of LPS-pretreated isolated arteries with intact endothelium. These results suggest the selectivity of OroA in ameliorating cardiovascular dysfunctions in endotoxemia. The successful rate of OroA in reversing LPS-induced hypotension in the present studies, however, is variable between 50% and 70% of different groups of animals examined. Similar results were found for OroA-induced endothelium-dependent constriction of isolated endotoxemic mesenteric arteries with endothelium. These variable results are consistent with the reported heterogeneity of ECs, which produce a wide range of vasoactive molecules for vasoconstriction and vasodilation (Kurosawa et al., 1998) and is differentially regulated in space and time (McCuskey et al., 1996; Aird, 2003) .
OroA, however, did not induce any constriction of LPS-induced endotoxemic mesenteric arteries denuded of endothelium. Similar results were found in endotoxemic aortic and tail arterial rings (unpublished data, T-L Tseng et al., Experimental Biology meeting, 2015), indicating that OroA-induced vasoconstriction is endotheliumdependent. It appears that LPS causes induction of some vasoconstrictor substance(s), which are absent or in extremely low concentrations in normal animals. The LPSinduced vasoconstrictor(s) is released specifically by OroA, causing rapid contraction of the vascular SMCs. This hypothesis of OroA-induced endothelium-dependent vasoconstriction is in line with the findings that posttreatment with baicalein or wogonin, which did not reverse the diminished hypotension in vivo, did not induce constriction of isolated LPS-pretreated mesenteric arteries with endothelium. These prompt-and-sustained vasoconstrictor effects of OroA are consistent with its rapid reversal of the hypotension in vivo.
Our present results provide strong evidence that ET-1 is the major vasoconstrictor in mediating OroA-induced endothelium-dependent constriction of endotoxemic mesenteric arteries. This is based on findings that isolated endotoxemic mesenteric arteries with intact endothelium (verified by ACh-induced vasorelaxation) significantly expressed ECE and ET-1 mRNAs and proteins. The increased ET-1 expression is consistent with earlier findings that circulating ET-1 was elevated in the earlier phase of sepsis (Baker, 1994; Curzen et al., 1997; Mitaka et al., 1998; Wanecek et al., 2000) with a LPS-induced time-dependent increase of expression of ET-1 mRNA. The expression of both ECE and ET-1 in LPS-treated mesenteric arteries was further enhanced by OroA. The expression of ECE and ET-1, however, was not seen in arteries denuded of endothelium even after treatments with LPS and/or OroA, supporting their increased expression in the endothelium. Finally, OroA-induced constriction of LPS-pretreated mesenteric arteries with endothelium was blocked by pre-treatment or post-treatment of antagonists for the ET A receptor (BQ123) and ET B receptor (BQ788) in a concentration-dependent manner (Yanagisawa et al., 1988; Mitaka et al., 1998; Wanecek et al., 2000) . These pharmacological results provide strong evidence suggesting that the OroA-induced, endothelium-dependent, constriction of mesenteric arteries was predominantly mediated by ET-1. The possibility of altered expression of ET-1 receptors in mediating increased OroA-induced vasoconstriction, however, is not likely, because expression of ET-1 receptors in mesenteric arteries was not affected by LPS and/or OroA treatments. These latter findings, however, contrasted with earlier results. For instance, LPS-induced time-dependent increase of ET-1 receptors in endotoxemic lung injury has been reported (Jesmin et al., 2011) . Also, ET A receptor mRNA expression in the brain is markedly increased after LPS-challenge, whereas expression of ET B receptors shows an initial up-regulation and then gradually decreases as sepsis progresses (Shimojo et al., 2006) . The exact reason for the difference in findings in different experimental conditions remains to be determined.
Another interesting finding of the present study is that both ET A and ET B receptor antagonists blocked OroA-induced constriction of endotoxemic mesenteric arteries, suggesting the presence of both receptors on the SMC of endotoxemic arteries. This is consistent with the report of the presence of ET B receptors on mesenteric SMC (Martinez-Revelles et al., 2012) , although it is widely known that ET A receptors are expressed on the SMC, while ET B receptors are peculiar to the ECs (Martinez-Revelles et al., 2012) . One likely possibility is that inhibition by BQ788 of ET B receptors on the endothelium blocks OroA-induced ET-1 release and therefore decreases vascular tone. This possibility is supported by the present findings (Figure 6 ) that in endotoxemic mesenteric arteries, blockade of ET B receptors by BQ788 inhibits OroA-induced ET-1 protein expression ( Figure 6C and D) with decreased ET-1 release. This is consistent with the report that BQ788 pretreatment suppressed the increased ET-1 mRNA in injured (by crushing) optic nerves (Tonari et al., 2012) . These results further support the hypothesis that OroA-induced endothelium-dependent constriction of mesenteric arteries is mediated by ET-1. Other reports, however, have indicated that exogenous ET-1 reduced cellular ET-1 mRNA, while ET B -selective antagonists increased ET-1 mRNA in porcine aortic ECs (Farhat et al., 2008) . The exact role of OroA in modulating endothelial ET B receptors and endothelial ET-1 expression in endotoxemic mesenteric arteries deserves detailed examination.
OroA-induced constriction of endotoxemic mesenteric arteries also was blocked by inhibitors of ROCK, suggesting the possibility that ET-1 induced vasoconstriction by activating the RhoA/ROCK pathway in the SMCs (Buyukafsar et al., 2004) . Indeed, OroA, but not wogonin or baicalein, reversed the diminished RhoA-activity induced by LPS in arteries with endothelium, while in arteries without endothelium, OroA did not affect the diminished RhoA-activity induced by LPS. OroA, but not wogonin or baicalein, also increased ROCK-activities in endotoxemic mesenteric arteries with intact endothelium. The ROCK activities, indicated by increased phosphorylated-ROCKII-Ser 1366 (p-ROCK)-immunoreactive SMCs, proteins and fluorescence intensity with increased number of the contracted SMCs of LPS-treated arteries with endothelium were blocked by the ET A and ET B receptor antagonists (Figures 5, 6 ). These findings further support the hypothesis that OroA-induced constriction of LPS-treated mesenteric arteries with intact endothelium is mediated predominantly by ET-1. The finding of failure of OroA in reversing diminished RhoA-activities or increasing ROCK activities in LPS-treated mesenteric arteries without endothelium also strengthens the hypothesis of endothelium-dependency of OroA-induced vasoconstriction in endotoxemic arteries. The suggestion that OroA-induced endotheliumdependent vasoconstriction is mediated by activation of the RhoA/ROCK pathway in the SMCs is reasonable and important. The small G protein RhoA and its downstream effector ROCK are reported to mediate contraction of the vascular SMC via increased Ca 2+ influx (Martinsen et al., 2012) and Ca 2+ sensitization (VanBavel et al., 2001; Chitaley and Webb, 2002; Chan et al., 2009) . Particularly, in the late stage of endotoxemia, excessive production of NO catalysed by iNOS inhibits RhoA activity, leading to vascular hyporeactivity (Liao et al., 2013) . Hence, restoration of the endogenous RhoA/ROCK pathway by OroA in endotoxemic shock arteries appears to play a role in ameliorating vascular hyporeactivity. OroA, therefore, is a novel 'indirect' RhoA/ROCK pathway activator, using an endothelium-dependent mechanism to improve vascular reactivity in endotoxemic shock. That is, OroA does not directly activate RhoA/ROCK pathway in the SMCs. The failure of wogonin and baicalein in reversing the diminished RhoA/ROCK activities in LPS-pretreated arteries with intact endothelium, again, is consistent with the findings that neither compound reverses endotoxemic hypotension or constricts LPS-pretreated arteries with or without endothelium. Although wogonin and baicalein post-treatments in our present study were ineffective in ameliorating acute endotoxemic shock, pre-treatments of both compounds may delay the development of LPS-induced experimental endotoxemia (Van Dien et al., 2001; Cheng et al., 2007) . Furthermore, OroA inhibition of iNOS expression in the arterial wall (present study) and other organs such as the liver and kidney (our unpublished data) leading to decreased circulating NO, theoretically may contribute to its 'vasoconstrictor' effect. This effect of OroA, however, does not mediate its immediate reversal of the cardiovascular dysfunction, because it is known that OroA does not directly inhibit iNOS activity . Rather, OroA acts by inhibiting genomic expression of iNOS proteins, which takes hours Chen et al., 2001) . Moreover, inhibition of iNOS activity is shared by wogonin and baicalein Chen et al., 2001) , which, as already been stated, do not reverse endotoxemic hypotension or cause endothelium-dependent vasoconstriction. It is, therefore, logical to propose that the OroA-induced endotheliumdependent vasoconstriction of endotoxemic mesenteric arteries was not due to inhibition of endothelium NO synthesis and/or release either. Although Tsang et al. (2000) reported that baicalein might potentiate vasoconstrictor-evoked contractile response through inhibition of endothelial NO formation and/or release in normal rat mesenteric arteries, others have demonstrated that OroA-induced relaxation of normal rat aortic rings may be due partly to release of endothelial NO . Furthermore, pre-treatment and post-treatment with 1400 W or L-NNA did not block OroA-induced constriction of LPS-pre-treated isolated arteries in vitro (our unpublished data). These results suggest that OroA-induced prompt vasoconstriction and reversal of systemic hypotension in endotoxemic rats were not caused by direct inhibition of NOS pathway or NO-related metabolites.
The inhibition of systemic iNOS expression leading to decreased circulating NO, however, may contribute to the maintenance of systemic BP in the later stage of the endotoxemia (Nava et al., 1991; Hallemeesch et al., 2003) . In the present study, hypotension in the late stage (18 h after LPS-treatment) of endotoxemia is accompanied by a 20-fold increase of circulating NO. This concentration of NO was decreased by OroA administered (i.v.) 1 or 6 h after LPS challenge. The decreased NO concentration, then, lessens NO inhibition of RhoA activity (Liao et al., 2013) , thereby enhancing OroA-induced vasoconstriction. These results suggest that OroA is effective in ameliorating the earlier (via release of endothelium-derived vasoconstrictors including ET-1) and the later (via release of endothelium-derived vasoconstrictors and inhibition of NO synthesis) phases of hypotension caused by LPS.
Clinically, AVP is used to raise systemic BP in hypotensive shock because of its direct vascular smooth muscle constricting effect (Russell, 2007; Lange et al., 2008; Kampmeier et al., 2010) . This direct vasoconstrictor effect of AVP and its peptidic analogue, FE202158 (Laporte et al., 2011) , however, may also decrease coronary blood flow and potentially worsen the already weakened hearts in both experimental and clinical settings (Russell, 2007; Kampmeier et al., 2010; Kimmoun et al., 2013) . ET-1 is, similarly, not indicated for the acute treatment of septic hypotensive shock (Weitzberg et al., 1993; Wanecek et al., 2000) because of its constriction of all arteries including the coronary (Ezra et al., 1989; Weitzberg et al., 1993) . Surprisingly, OroA does not cause coronary vasoconstriction in endotoxemic hearts (Liu et al., 2012a) , although it induced endothelium-dependent constriction of endotoxemic large mesenteric arteries, and promptly reversed systemic hypotension and bradycardia in endotoxemic rats. In LPS-induced isolated endotoxemic hearts, the decreased coronary flow and inotropy (5 h after LPS challenge) were ameliorated by OroA but were further aggravated by AVP (Liu et al., 2012a) . This study by Liu et al. (2012a demonstrates that OroA ameliorates LPS-depressed cardiac functions by increasing coronary flow (i.e. coronary vasodilation), leading to positive inotropy. This effect of OroA was endothelium-independent and was due to its direct relaxation of the coronary SMCs (Liu et al., 2012a) . This beneficial cardiac effect of OroA is supported by the positive chronotropic effect of OroA in vivo as shown in the present study. These results favour the possibility of improvments in the coronary microcirculation by OroA and reveal the difference between LPS-treated ECs of the coronary artery and those of other peripheral large arteries such as the mesenteric arteries, further supporting the heterogeneity of ECs (McCuskey et al., 1996; Aird, 2003) .
Another potential concern in the use of AVP and its peptidic analogue is that their actions through V 1A receptors display rapid tachyphylaxis (Erwald, 1976; Hamel et al., 2005) . This desensitization of V 1A receptors may have a pathophysiological importance in sepsis, during which these peptidic analogues may be insufficient to raise BP to assure an appropriate perfusion to vital organs. In contrast, OroAinduced endothelium-dependent sustained constriction of the large arteries lasted for hours without tachyphylaxis, as shown in the present studies. These effects of OroA from in vivo and in vitro studies, therefore, suggest the potential benefits of OroA via endothelium-dependent constriction of large arteries in managing septic shock, especially, in patients with cardiac dysfunction (Liu et al., 2012a) .
The significance of OroA-induced endothelium-dependent constriction of endotoxemic arteries is not limited to the mesenteric arteries. Our preliminary studies demonstrated that OroA also induced endothelium-dependent ROCK-mediated constriction of the endotoxemic aorta and tail arteries of the rat (unpublished data, Tseng et al., Abstract for Experimental Biology, 2015) . The endotheliumdependent vasoconstriction in both arteries, however, was not appreciably affected by ET-1-receptor antagonists, suggesting that the ECs of these endotoxemic arteries release non-ET-1 vasoconstrictor(s). The different effects of OroA on endothelial expression and release of various vasoconstrictors in different vascular beds in endotoxemia are interesting, further suggesting heterogeneous distributions of ET-1 and other vasoconstrictors among different vascular beds in sepsis. This again is consistent with the reported EC heterogeneity or vascular diversity in sepsis (McCuskey et al., 1996; Aird, 2003) . Although the chemical nature of these non-ET-1 vasoactive substances remains to be determined, OroA-induced endothelium-dependent constriction of large arteries of the endotoxemic rats is clear and is expected to offer a useful strategy for acute reversal of the endotoxemic hypotensive shock.
In summary, in addition to its anti-inflammatory effect, OroA post-treatment promptly reversed LPS-induced endotoxemic hypotension. This cardiovascular effect of OroA is likely to be due to its release of LPS-induced vasoconstrictors from the endothelium of large arteries, such as ET-1 in the mesenteric arteries, causing vasoconstriction by activating the RhoA/ROCK pathway in the vascular SMCs. It is highly possible that different vasoconstrictor(s) could be induced by LPS in ECs of arteries from different regions. OroA post-treatment also decreases circulating NO, resulting in decreased NO-induced vasodilation and NO inhibition of RhoA/ROCK pathway. The latter effect further facilitates OroA-induced vasoconstriction ( Figure 6H ). The present results obtained from studying vascular effects of OroA indicate that combination of anti-inflammation and induction of endothelium-dependent constriction of large resistant arteries may provide an alternative strategy in preventing and managing endotoxemic hypotensive shock. Furthermore, the region-variable effects of the endotheliumdependent vasoconstriction may allow manipulation of specific regions or organs in the treatment of endotoxemic shock. The endothelium-dependent vasoconstriction induced by OroA, therefore, may exhibit advantages over that induced by direct smooth muscle contractors in treating endotoxemic hypotensive shock, especially in patients with complication due to cardiac dysfunction.
in the columns represent number of experiments. In parallel, the plasma NO concentrations (panels B and C) were significantly increased in LPS-challenged rats in the course of study for 24 hours with the peak concentration occurred around 12 hours after LPS challenge. The plasma concentrations of NO were significantly decreased by OroA (15 mg/kg, iv) administered 1 hour (panel B) or 6 hours (panel C) after LPS challenge. Plasma concentration of NO in normal control group (Sal "challenge", iv, followed by Solv1, iv, 1 hour later) remained unchanged during the entire course of study (panel B) . Data are means±SEM. *P<0.05 indicates significantly different between the compared groups in panel A. *P<0.05 indicates significant difference from the normal control group, and #P<0.05 indicates significantly different from the LPS (iv)-treated group followed by Solv1 (iv) 1 hour or 6 hours later in panels B and C. Solv1 (normal saline plus tween 80 at 9:1 ratio); Posttreat (post-treatment after LPS challenge). n= number of experiments. Figure S4 OroA suppression of LPS-activated NF-B signaling in mesenteric arteries. One hour (h) (Lane 2 in panel A) or 6 hours (Lane 4 in panel A) after LPS challenge (10 mg/kg, iv) in endotoxemic rats, phosphorylated I B in isolated mesenteric arteries with endothelium was significantly increased compared to that in normal controls. Normal saline (Sal) was administered (iv) and followed by Solv1 (iv) 1 hour later (Lane 1 in panel A) served as normal control. The increased I B was significantly suppressed by OroA (15 mg/kg, iv, in Lane 3 in panel A) administered 1 hour (Lane 3 in panel A) or 6 hours (Lane 5 in panel A) after LPS-challenge. Actin levels served as internal control. Panel B indicates that LPS treatment (10 mg/kg, iv) significantly increased nuclear phosphorylated NF-Bp65 expression (Lane 2 in panel B) compared to that of the respective controls (normal saline challenge followed by Solv1 treatment, Lane 1 in panel B) in isolated mesenteric arteries. Phosphorylated NF-Bp65 proteins were significantly reduced by OroA (15 mg/kg, iv) administered 1 hour (Lane 3 in panel B) or 6 hours (Lane 5 in panel B) after LPS 13 challenge. H2A levels served as internal control. Posttreat (treatment after LPS-challenge). Data are means±SEM. *P<0.05 indicates significantly different between the compared groups. The number in each column represents the number of rats examined.
